Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease – a randomized, open-label, multicenter phase II trial

Fig. 1

TREASURE study design. ED SCLC patients with any response (defined as CR/PR or thoracic SD with CR/PR of extrathoracic lesions) after four cycles of standard chemo-immunotherapy consisting of carboplatin/etoposide and atezolizumab will be randomized to either receive thoracic radiotherapy or not. All patients will receive maintenance atezolizumab therapy until disease progression or occurrence of intolerable toxicities

Back to article page